Stability, purity, synthesis, and formulation — the chemistry and manufacturing details that separate a quality product from a risky one.
Colston et al. clarified the molecular mechanism by which salcaprozate sodium (SNAC) — the absorption enhancer in oral semaglutide (Rybelsus) — lets peptides cross the gut epithelium. They show SNAC inserts into cell membranes and generates transient, fluid defects through which peptides like semaglutide slip. The work helps explain why oral semaglutide needs roughly 400 mg of SNAC for just 7–14 mg of peptide, and could inform next-generation oral peptide formulations beyond GLP-1s.
A denoising diffusion model from David Baker's Institute for Protein Design generates macrocyclic peptide binders against arbitrary protein targets. Tested on four targets, it produced nanomolar-affinity binders from fewer than 20 designs each, with crystal structures matching the computational models to within ~1.5 Å. Published in Nature Chemical Biology, the work signals that AI can now yield drug-like cyclic peptides on demand.
Varró, Mándityné Huszka, Erdei, Mándoki and Mándity reported a continuous-flow solid-phase peptide synthesis platform that swaps toxic DMF/NMP for the greener solvent propylene carbonate. Published in Chemistry–Methods (May 2025), the method synthesized both α- and β-peptides at greater than 4-gram scale with good efficiency, pairing the throughput and automation advantages of continuous flow with a lower-toxicity, biodegradable solvent. The work tackles SPPS's chronic environmental weakness — huge volumes of hard-to-dispose polar aprotic solvents and a notoriously high Process Mass Intensity. As GLP-1-driven demand scales peptide manufacturing, greener high-throughput routes are becoming both a regulatory and a cost imperative.
On January 8, 2025, PolyPeptide Group announced a roughly €100 million investment to double solid-phase peptide synthesis (SPPS) capacity at its Malmö, Sweden plant, adding around 100 permanent jobs. The expansion is mainly tied to a long-standing GLP-1 customer agreement under one of the company's large commercial deals, with revenue contribution expected to begin in 2028. It reflects the global manufacturing crunch driven by GLP-1 agonist demand, which has outstripped existing peptide-API capacity and triggered comparable multi-hundred-million-euro build-outs at rivals such as Bachem and Lonza. Modular pre-built units were installed on-site during 2025 so existing production could keep running through the build-out.